Previous 10 | Next 10 |
Athersys, Inc. (ATHX) Q1 2020 Results Earnings Conference Call May 07, 2020, 04:30 PM ET Company Participants Karen Hunady - Director of Corporate Communications and Investor Relations Gil Van Bokkelen - Founder, Chairman and Chief Executive Officer Ivor Macleod - Chief Financial...
The following slide deck was published by Athersys, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Management to host conference call at 4:30 pm EDT today Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2020. Highlights of the first quarter of 2020 and recent events include: Received authorization from the U.S. Foo...
The SARS-CoV2 pandemic has ignited a massive effort across the globe, led by medical researchers and biotech companies, to come up with therapies that can help patients and bring an end to the pandemic. Vaccines, antibodies, immunity and convalescent plasma have all become common medical ter...
Akari Therapeutics Releases Positive Top Line Data Akari Therapeutics ( AKTX ) reported encouraging results from its Phase 2 study of Nomacopan. The study met its primary endpoint which was related to no drug-related adverse events. The drug candidate was granted Orphan Drug designation ...
Enrollment is underway in a pivotal Phase 2/3 clinical trial evaluating Athersys' (NASDAQ: ATHX ) MultiStem cell therapy in COVID-19 patients with acute respiratory distress syndrome. More news on: Athersys, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Rapid advancement of clinical program for the treatment of ARDS based on prior clinical data reflecting favorable tolerability data and meaningful benefits on mortality, ventilator-free days and ICU-days Athersys, Inc. (NASDAQ: ATHX) announced today that the first patients have b...
Shares of Athersys (NASDAQ: ATHX) declined more than 23% last month, according to data provided by S&P Global Market Intelligence . By comparison, the S&P 500 rose 12.7% in one of its best months on record. But investors might not be too concerned. The stem cell stock's April decl...
Medigus (NASDAQ: MDGS ) +76% on first order for COVID-19 blood test . More news on: Medigus Ltd., Myomo, Inc., Akari Therapeutics, Plc, Stocks on the move, , Read more ...
Athersys (NASDAQ: ATHX ) and University Hospitals Cleveland Medical Center (UH Cleveland) announce that latter is now open as the first clinical site for the MACOVIA (MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome) trial. More news on: Athersys, Inc., H...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...